Orphan drug designation granted by FDA for envafolimab in soft tissue sarcoma
Envafolimab is a single-domain antibody against PD-L1. Orphan designation was granted on the basis of phase 1 data showing partial responses by RECIST with duration of response in excess of six months.
Source:
Biospace Inc.